Company / Financials
TEVA PHARMACEUTICAL INDUSTRIES LTD Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$17.3B
FY2025 · +4.3% YoY
Net Income
$1.4B
FY2025 · +186.0% YoY
Profit Margin
8.2%
FY2025 · net income / revenue
ROE
17.8%
FY2025 · return on equity
Total Assets
$40.7B
FY2025
Total Debt
-
FY2025
Equity
$7.9B
FY2025
ROA
3.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$17.3B+4.3% YoYNet Income HistoryProfit after all expenses and taxes$1.4B+186.0% YoYGross Profit HistoryRevenue minus cost of goods sold$8.9B+10.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$8.3B-1.9% YoYOperating Income HistoryProfit from core business operations before interest and taxes$2.2B+811.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$1.3B+10.9% YoYR&D Expense HistoryResearch and development spending$1.0B+1.5% YoYInterest Expense HistoryCost of borrowing and debt obligations$916.0M-8.6% YoYIncome Tax HistoryTotal income tax expense-$180.0M-126.6% YoYEPS (Basic) HistoryBasic earnings per share-$0.50+77.3% YoY